| Literature DB >> 32457257 |
Younghuen Shin1, Jinsoo Rhu1, Gyu-Seong Choi1, Jong Man Kim1, Jae-Won Joh1, Choon Hyuck David Kwon1.
Abstract
BACKGROUNDS/AIMS: While minimal invasive surgery has become popular, the feasibility of laparoscopy for liver cavernous hemangioma has not been shown.Entities:
Keywords: Cavernous hemangioma; Hemangioma; Laparoscopic liver resection; Laparoscopy
Year: 2020 PMID: 32457257 PMCID: PMC7271101 DOI: 10.14701/ahbps.2020.24.2.137
Source DB: PubMed Journal: Ann Hepatobiliary Pancreat Surg ISSN: 2508-5859
Surgical resections performed from January 2008 to February 2019 for liver cavernous hemangioma
| Laparoscopy (n=41) | Open (n=43) | |
|---|---|---|
| Subsegmentectomy | 4 (9.8%) | 2 (4.7%) |
| Segmentectomy | 4 (9.8%) | 2 (4.7%) |
| Sectionectomy | 11 (26.8%) | 6 (14.0%) |
| Central hepatectomy-3 segments | 1 (2.4%) | 1 (2.3%) |
| Central hepatectomy-4 segments | 0 (0%) | 1 (2.3%) |
| Hemihepatectomy | 18 (43.9%) | 14 (32.6%) |
| Extended hemihepatectomy | 3 (7.3%) | 9 (20.9%) |
| Trisectionectomy | - | 8 (18.6%) |
Comparison of the background characteristics between the laparoscopy group and open surgery group
| Variables | Laparoscopy (n=43) | Open (n=33) | |
|---|---|---|---|
| Sex (M/F) | 7/36 | 12/21 | 0.062 |
| Age, mean±SD (years) | 46.4±10.3 | 50.6±11.2 | 0.095 |
| Body mass index, mean±SD (kg/m2) | 22.7±3.6 | 22.3±3.0 | 0.445 |
| Indication for surgery (Symptom vs. other) | <0.001 | ||
| Symptom | 6 (14.6%) | 20 (57.1%) | |
| Increase in size | 32 (78.0%) | 10 (28.6%) | |
| Possibility of malignancy | 3 (7.3%) | 5 (14.3%) | |
| ASA score | 0.664 | ||
| Class I | 24 (58.5%) | 18 (51.4%) | |
| Class II/III | 17 (41.5%) | 17 (48.6%) | |
| Major operation of upper abdomen (%) | 3 (7.3%) | 1 (2.9%) | 0.231 |
| Preoperative test | |||
| Hemoglobin, median (g/dl Q1-Q3) | 12.6 (11.8-13.3) | 12.8 (11.7-14.5) | 0.438 |
| Platelet, median (×103/μl) | 215.0 (167.0-249.0) | 199.0 (140.5-227.5) | 0.130 |
| Albumin, median (g/dl) | 4.5 (4.3-4.7) | 4.2 (4.1-4.6) | 0.020 |
| Total bilirubin, median (mg/dl) | 0.6 (0.3-0.8) | 0.7 (0.5-1.3) | 0.073 |
| Aspartate aminotransferase, median (U/L) | 18.0 (14.0-21.0) | 21.0 (17.0-24.0) | 0.059 |
| Alanine aminotransferase, median (U/L) | 13.0 (10.0-20.0) | 16.0 (11.0-23.0) | 0.339 |
| Prothrombin time, INR, median (U/L) | 1.00 (0.95-1.05) | 1.02 (0.99-1.10) | 0.079 |
| Pathologic data | |||
| Location | 0.017 | ||
| Right side | 14 (32.5%) | 21 (63.6%) | |
| Both | 3 (7.0%) | 2 (6.1%) | |
| Left side | 26 (60.5%) | 10 (30.3%) | |
| Number of tumors | 0.778 | ||
| Single (%) | 33 (76.7%) | 27 (81.8%) | |
| Multiple (%) | 10 (23.3%) | 6 (18.2%) | |
| Size, median (cm Q1-Q3) | 10.5 (6.2-14.0) | 9.5 (6.9-14.8) | 0.769 |
| Surgical extent | 0.101 | ||
| Less than 4 segments | 22 (51.1%) | 10 (30.3%) | |
| 4 segments or more | 21 (48.9%) | 23 (69.7%) |
ASA, american society of anesthesiologists; INR, International normalized ratio
Comparison of operative and postoperative data between the laparoscopy group and open surgery group
| Variables | Laparoscopy (n=43) | Open (n=33) | |
|---|---|---|---|
| Operative data | |||
| Operation time, mean±SD (min) | 217.0±110.6 | 265.2±98.7 | 0.058 |
| Estimated blood loss, median (cc Q1-Q3) | 300.0 (100.0-400.0) | 400.0 (257.5-1000.0) | 0.001 |
| Transfusion (%) | 1 (2.4%) | 8 (22.9%) | 0.035 |
| Postoperative data | |||
| Total bilirubin, median (mg/dl Q1-Q3) | 1.30 (0.80-1.70) | 1.90 (1.45-2.45) | 0.001 |
| Aspartate aminotransferase, median (U/L) | 160.0 (100.0-258.0) | 209.0 (127.0-300.5) | 0.374 |
| Alanine aminotransferase, median (U/L) | 163.0 (95.0-271.0) | 166.0 (119.5-273.5) | 0.579 |
| Prothrombin time, INR, mean±SD (U/L) | 1.28±0.18 | 1.41±0.22 | 0.003 |
| Postoperative recovery | |||
| Hospital stay, median (days Q1-Q3) | 7.0 (6.0-9.0) | 9.0 (8.0-10.0) | 0.001 |
| Starting day of soft diet, median (days) | 2.0 (1.0-2.0) | 4.0 (3.0-4.0) | <0.001 |
| Removal of drainage catheter, median (days) | 4.0 (3.0-5.0) | 5.0 (5.0-7.0) | <0.001 |
| Amount of additional opioid, median (times) | 1.0 (0.0-3.0) | 3.0 (2.0-6.0) | 0.001 |
| Last day for additional opioid, median (days) | 2.0 (0.0-4.0) | 3.0 (2.0-5.0) | 0.017 |
| Complications (%) | 4 (9.3%) | 4 (12.1%) | 0.721 |
| Clavien-Dindo classification | 0.621 | ||
| None | 39 (90.7%) | 29 (87.9%) | |
| I/II | 3 (7.0%) | 2 (6.1%) | |
| III/IV/V | 1 (2.3%) | 2 (6.0%) | |
| Pathologic report | |||
| Carvernous hemangioma | 43 (100%) | 33 (100%) | |
| Malignancy or others | 0 (0%) | 0 (0%) | |
| Postoperative symptom evaluation | 0.576 | ||
| No symptom or subsided | 42 (97.7%) | 31 (93.9%) | |
| Symptom deteriorated or newly occurred | 1 (2.3%) | 2 (6.1%) |
INR, International normalized ratio
Characteristics of patients who underwent trisectionectomy for liver cavernous hemangioma
| Variables | Number or mean (median) |
|---|---|
| Sex (Female/male) | 8/0 |
| Mean age (years) | 54.3±11.3 |
| Mean BMI | 23.5±3.5 |
| ASA 1/2/3 | 3/5/0 |
| Median tumor size (range) | 15.75 (8-35) |
| Site of tumor | |
| Right | 4 (50.0%) |
| Both | 2 (25.0%) |
| Left | 2 (25.0%) |
| Operative data | |
| Operation time, median | 465 (211-607) |
| EBL, median | 900 (150-3200) |
| Transfusion (%) | 4 (50.0%) |
| Postoperative data | |
| Hospital stay, median | 21 (8-74) |
| Soft diet, median | 4 (2-5) |
| Removal of drain, median | 13.5 (7-74) |
| Amount of additional opioid, median | 3 (1-15) |
| Day for additional opioid, median | 3 (1-12) |
| Complications | 6 (75.0%) |
| Clavien-Dindo Classification | |
| II | 2 (25.0%) |
| IIIa | 1 (12.5%) |
| IIIb | 3 (37.5%) |